Targeting CTSS has emerged as a therapeutic strategy for autoimmune diseases (e.g., rheumatoid arthritis, asthma, desiccation syndrome, multiple sclerosis) due to its dual role in MHC-II maturation and DC motility (80–83). The gene discussed is CTSS; the disease is multiple sclerosis.